Please use this identifier to cite or link to this item:
Título : Melatonin : highlighting its use as a potential treatment for SARS‑CoV‑2 infection
Autor : Reiter, R. 
Sharma, Ramaswamy 
Simko, Fedor 
Domínguez Rodriguez, Alberto 
Tesarik, Jan 
Neel, Richard L. 
Slominski, Andrzej T. 
Kleszczynsk, Konrad 
Martin‑Gimenez, Verna M. 
Manucha, Walter 
Cardinali, Daniel Pedro 
Fecha de publicación : 2022
Editorial : Springer
Cita : Reiter, R. et al. Melatonin : highlighting its use as a potential treatment for SARS‑CoV‑2 infection [en línea]. Cellular and Molecular Life Sciences. 2022, 79 (143). doi: 10.1007/s00018-021-04102-3. Disponible en:
Resumen : Abstract: Numerous pharmaceutical drugs have been repurposed for use as treatments for COVID-19 disease. These drugs have not consistently demonstrated high efcacy in preventing or treating this serious condition and all have side efects to difering degrees. We encourage the continued consideration of the use of the antioxidant and anti-infammatory agent, melatonin, as a countermeasure to a SARS-CoV-2 infection. More than 140 scientifc publications have identifed melatonin as a likely useful agent to treat this disease. Moreover, the publications cited provide the rationale for the use of melatonin as a prophylactic agent against this condition. Melatonin has pan-antiviral efects and it diminishes the severity of viral infections and reduces the death of animals infected with numerous diferent viruses, including three diferent coronaviruses. Network analyses, which compared drugs used to treat SARS-CoV-2 in humans, also predicted that melatonin would be the most efective agent for preventing/treating COVID-19. Finally, when seriously infected COVID-19 patients were treated with melatonin, either alone or in combination with other medications, these treatments reduced the severity of infection, lowered the death rate, and shortened the duration of hospitalization. Melatonin’s ability to arrest SARS-CoV-2 infections may reduce health care exhaustion by limiting the need for hospitalization. Importantly, melatonin has a high safety profle over a wide range of doses and lacks signifcant toxicity. Some molecular processes by which melatonin resists a SARS-CoV-2 infection are summarized. The authors believe that all available, potentially benefcial drugs, including melatonin, that lack toxicity should be used in pandemics such as that caused by SARS-CoV-2.
Disciplina: MEDICINA
DOI: 10.1007/s00018-021-04102-3
Derechos: Acceso abierto
Appears in Collections:Artículos

Files in This Item:
File Description SizeFormat
melatonin-highlighting-use.pdf1,26 MBAdobe PDFThumbnail
Show full item record

Page view(s)

checked on Jun 6, 2023


checked on Jun 6, 2023

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons